NETRF’s investments have a multiplier effect on the NET research landscape to unlock NET mysteries and propel the development of new treatments in the search for a cure. As the largest private global funder of NET research, NETRF is leading the fight to bring life-changing treatments to patients. More often than not, NETRF is the only funding source available for many scientists working to understand this complicated and uncommon cancer.
Driving the search for a cure to neuroendocrine cancer
Since its inception in 2005, NETRF has awarded $36 million in large-scale, multi-year research grants to leading scientists at renowned institutions around the world, with the goal of:
- Understanding the molecular underpinnings of the disease to discover vulnerabilities that can be exploited to interrupt the development and progression of NETs.
- Discovering diagnostic and prognostic markers that can guide treatment planning and sequencing decisions.
- Developing reliable disease models for laboratory experiments of new treatments.
- Creating a collaborative NET scientific community where researchers openly share resources, tools, and ideas.
- Increasing the number of NET researchers focused on discovering breakthroughs in treatment
Improving the lives of those with neuroendocrine cancer
The Neuroendocrine Tumor Research Foundation is committed to improving the lives of patients, families, and caregivers affected by neuroendocrine cancer by providing information and educational resources.
- Online resources to help newly diagnosed patients chart their course and practical information to help NET survivors live their best life.
- Searchable databases of NET specialists and support groups in the U.S.
- Regional patient and caregiver conferences bring together patients and providers to discuss the latest tests and treatments.
- Multimedia library on the latest information on treatment and disease management approaches
The latest in NET News
Early NETRF-funded research identifies a potential prognostic biomarker to help physicians predict neuroendocrine cancer outcomes.
NETRF Annual Report 2019 looks at scientific milestones and educational innovations. It includes stories about some of the people who have supported us to fund more research projects than ever before and offer new ways to learn about NETs.
NETRF’s Director of Research John Kanki, PhD, provides an update on the status of ongoing NETRF-funded research studies during COVID-19.